Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 3;10:435. doi: 10.3389/fonc.2020.00435

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Panina, Pei, Baran, Konopleva and Kirienko.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effect of selected mitocan-based drug combinations on other types of leukemia. (A,B) Synergy landscapes for ALL, (A) (CCRF-CEM cells, left, or MOLT-4 cells, right) or CML, (B) (K-562 cells, left, or KU812 cells, right) treated with IACS-010759/vinorelbine, rotenone/2-deoxy-D-glucose, CCCP/dasatinib, or ABT-199/lonidamine. Drug combination landscapes: z-axis, synergy score (ranges from −40, green, to +40, red); x/y-axes, drug1/drug2 concentration range, respectively. Drug combination landscapes were built using Bioconductor package “synergyfinder.” One representative replicate (with maximal synergy closest to the average value of three biological replicates) is shown. For specific drug names and drug concentrations, refer to Table S4.